[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
2. Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB: Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol; 2000 Feb;18(4):860-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
  • The present study was designed to evaluate the rates of hepatic toxicity and biliary stent-related complications and to evaluate the impact of this morbidity on the delivery of preoperative chemoradiation for pancreatic cancer at a tertiary care cancer center.
  • PATIENTS AND METHODS: Preoperative chemoradiation was used in 154 patients with resectable pancreatic adenocarcinoma (142 patients, 92%) or other periampullary tumors (12 patients, 8%).
  • CONCLUSION: Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent-related complications.
  • The need for biliary decompression is not a clinically significant concern in the delivery of preoperative therapy to patients with localized pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Ducts / pathology. Neoadjuvant Therapy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Stents / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy. Common Bile Duct Neoplasms / surgery. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Hospitalization. Humans. Incidence. Liver / drug effects. Liver / radiation effects. Male. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10673529.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country.
  • The overall five-year survival rate is 4 percent, and localized, resectable disease has only a 17 percent survival rate.
  • Risk factors include smoking, certain familial cancer syndromes, and familial chronic pancreatitis.
  • The link between risk of pancreatic cancer and other factors (e.g., diabetes, obesity) is less clear.
  • Most patients present with obstructive jaundice caused by compression of the bile duct in the head of the pancreas.
  • Epigastric or back pain, vague abdominal symptoms, and weight loss also are characteristic of pancreatic cancer.
  • Computed tomography is the most useful diagnostic and staging tool.
  • The majority of tumors are not surgically resectable because of metastasis and invasion of the major vessels posterior to the pancreas.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Other agents are being studied.
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


5. Rauws EA: Photodynamic therapy and Klatskin tumour: an overview. Scand J Gastroenterol Suppl; 2006;(243):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of patients with an unresectable bile duct cancer is poor.
  • In 60-70% of patients, cholangiocarcinoma is located in the hepatic duct bifurcation and known as Klatskin tumour.
  • Recently, the first prospective, randomized controlled study with PDT in a selected group of non-resectable cholangiocarcinoma patients was stopped prematurely.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Hepatic Duct, Common / pathology. Klatskin Tumor / drug therapy. Photochemotherapy
  • [MeSH-minor] Cholangiocarcinoma / drug therapy. Clinical Trials as Topic. Humans

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782632.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 28
  •  go-up   go-down


6. Matsuo R, Kondo T, Ohshiro Y, Moon Y, Yamamoto Y, Takeshima T, Todoroki T, Ohkohchi N: [A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1501-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine].
  • We reported a case of non-resectable intrahepatic biliary tract cancer, treated with Gemcitabine and oral anticancer drugs.
  • CT scan revealed intrahepatic biliary tract cancer in the left lobe, which had metastasized to both lobes.
  • Based on the diagnosis of non-resectable intrahepatic biliary tract cancer, systemic chemotherapy using gemcitabine (GEM) was employed.
  • At the same time, the oral anti-cancer drug (5'-DFUR 600 mg/day) was administered every day.
  • The present case shows that gemcitabine/5'-DFUR combination is well supported in advanced unresectable biliary tract cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Deoxycytidine / analogs & derivatives. Liver Neoplasms / secondary
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Drug Administration Routes. Floxuridine / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033247.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


7. Isayama H: Current topics in pancreato-biliary endotherapy: what can we do? J Hepatobiliary Pancreat Surg; 2009;16(5):589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CMS is effective not only for unresectable biliary malignancies but also for resectable tumors, benign biliary strictures, and benign pancreatic strictures.
  • Drug-eluting CMS can be used as anti-tumor agents.
  • The diagnosis and treatment of pancreatic cancer using interventional EUS technique are effective, feasible, and promising.
  • Endoscopic papillary large balloon dilation (EPLBD), new procedure to the papilla, can treat large bile duct stones effectively without lithotripsy.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543686.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 27
  •  go-up   go-down


8. Ustundag Y, Bayraktar Y: Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol; 2008 Nov 14;14(42):6458-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma (CC) is a devastating cancer arising from biliary epithelia.
  • These tumors progress insidiously, and liver failure, biliary sepsis, malnutrition and cancer cachexia are general modes of death associated with this disease.
  • However, our knowledge in tumor biology is increasing dramatically and new drugs are under investigation for treatment of this notorious tumor.
  • In clinical practice, there are better diagnostic tools in use to facilitate an earlier diagnosis of CC, at least in those patients with known risk factors.
  • CC is resectable for cure in only a small percentage of patients.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):7-13 [9496478.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):398-404 [9527063.001]
  • [Cites] Am J Surg. 1998 Jun;175(6):453-60 [9645771.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):651-8 [9725291.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):385-94 [9742921.001]
  • [Cites] Rofo. 1998 Dec;169(6):622-6 [9930216.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:122-6 [10436802.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):670-7 [10524843.001]
  • [Cites] Environ Health Perspect. 2005 Jan;113(1):43-8 [15626646.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6500-5 [12438243.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6):909-15 [12447312.001]
  • [Cites] J Hepatol. 2002 Dec;37(6):806-13 [12445422.001]
  • [Cites] Endoscopy. 2002 Dec;34(12):984-90 [12471543.001]
  • [Cites] Langenbecks Arch Surg. 2003 Jul;388(3):194-200 [12819970.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):45-51 [14687140.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):90-7 [14746840.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G88-95 [14977638.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):95-101 [15213624.001]
  • [Cites] Gastrointest Endosc. 2004 Jul;60(1):68-75 [15229428.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1684-9 [15330902.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1327-32 [15505298.001]
  • [Cites] Cancer. 1982 Oct 1;50(7):1408-15 [6286094.001]
  • [Cites] Radiology. 1988 Dec;169(3):635-9 [3055028.001]
  • [Cites] Am J Surg. 1990 Jan;159(1):91-7; discussion 97-8 [1688486.001]
  • [Cites] Lancet. 1990 Jan 13;335(8681):116-7 [1967406.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1091-5 [15754387.001]
  • [Cites] J Gastrointest Surg. 2005 Apr;9(4):476-80 [15797226.001]
  • [Cites] Ann Surg. 2005 May;241(5):703-12; discussion 712-4 [15849506.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Eur J Cancer Prev. 2005 Jun;14(3):245-50 [15901993.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):533-9 [15922889.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1158-63 [16000285.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4742-54 [16034050.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5239-40 [16127762.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61 [16135931.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):731-3 [16341314.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):851-7 [17352013.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):364-9 [17643714.001]
  • [Cites] World J Gastroenterol. 2007 Jul 14;13(26):3531-9 [17659703.001]
  • [Cites] Scand J Gastroenterol. 2002 Oct;37(10):1205-11 [12408527.001]
  • [Cites] World J Surg. 2003 Mar;27(3):278-83 [12607051.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):663-71 [10561090.001]
  • [Cites] Gut. 2000 Jan;46(1):103-6 [10601064.001]
  • [Cites] Hepatology. 2000 Jan;31(1):7-11 [10613720.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Liver Transpl. 2000 May;6(3):309-16 [10827231.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):166-74 [10903592.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):111-4 [10982601.001]
  • [Cites] Gastrointest Endosc. 2000 Oct;52(4):534-40 [11023576.001]
  • [Cites] Hepatology. 2000 Nov;32(5):916-23 [11050039.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):520-7 [11059855.001]
  • [Cites] Gastrointest Endosc. 2000 Nov;52(5):635-8 [11060188.001]
  • [Cites] Mayo Clin Proc. 2001 Jan;76(1):29-33 [11155409.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):500-4 [11275896.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):360-5 [11322195.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):210-4 [11505067.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Nucl Med Commun. 2001 Dec;22(12):1277-85 [11711897.001]
  • [Cites] Semin Liver Dis. 2001 Nov;21(4):545-50 [11745042.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] Surgery. 2002 May;131(5):564-73 [12019411.001]
  • [Cites] Gut. 2002 Jul;51(1):128-9 [12077105.001]
  • [Cites] Am J Transplant. 2002 Sep;2(8):774-9 [12243499.001]
  • [Cites] BMC Cancer. 2002 May 3;2:10 [11991810.001]
  • [Cites] Am J Ind Med. 1990;18(1):19-24 [2378367.001]
  • [Cites] World J Surg. 1990 Jul-Aug;14(4):535-43; discussion 544 [2166381.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1758-62 [2167649.001]
  • [Cites] Semin Liver Dis. 1991 Feb;11(1):26-30 [1646485.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):27-30 [1370603.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Mo Med. 1993 Oct;90(10):656-7 [8232154.001]
  • [Cites] Surgery. 1994 Apr;115(4):488-94 [8165540.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):171-90 [8000995.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8 [7794082.001]
  • [Cites] Am J Gastroenterol. 1995 Nov;90(11):2015-9 [7485013.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1522-5 [8535808.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):493-7 [8864191.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):61-6 [8961369.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):26-34 [8988723.001]
  • [Cites] Gut. 1996 Dec;39(6):852-5 [9038668.001]
  • [Cites] Surgery. 1998 Feb;123(2):131-6 [9481397.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):536-42 [9496944.001]
  • (PMID = 19030196.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC2773330
  •  go-up   go-down


9. Nanashima A, Yamaguchi H, Shibasaki S, Ide N, Sawai T, Tsuji T, Hidaka S, Sumida Y, Nakagoe T, Nagayasu T: Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol; 2004 Nov;39(11):1095-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.
  • BACKGROUND: Photodynamic therapy (PDT) is a new palliative option in patients with non-resectable bile duct carcinoma (BDC).
  • METHODS: Five patients had extrahepatic BDC, two had intrahepatic cholangiocarcinoma, and one had ampullary carcinoma.
  • Cancer cells were microscopically detected in the stump of the hepatic duct in six patients, and biliary stenosis caused by remnant tumor was observed in one patient.
  • One patient had tumor recurrence with occlusion of the bile duct.
  • In two patients with occlusion caused by tumor growth, resolution of bile duct stenosis was noted on day 7.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / surgery. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm, Residual. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580404.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


10. Birk D, Beger HG: Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer. Curr Gastroenterol Rep; 2001 Apr;3(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.
  • Pancreatic cancer remains a highly malignant disease.
  • Therefore, the vast majority of pancreatic cancer patients receive palliative treatment.
  • Surgical palliation is offered to patients who are found not to have a resectable tumor.
  • The treatment of obstructive jaundice is managed by stenting of the common bile duct or by a surgical bypass.
  • As palliative chemotherapy alone, 5-fluorouracil (5-FU) plus folinic acid is still the treatment of choice; however, newer drugs, such as gemcitabine, seem to have similar or marginally better results.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1994 Jan;81(1):102-7 [7906180.001]
  • [Cites] World J Surg. 1999 Sep;23(9):907-12 [10449819.001]
  • [Cites] Can J Gastroenterol. 1999 Jul-Aug;13(6):481-7 [10464348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] Gut. 1989 Aug;30(8):1132-5 [2475392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1015-25 [8083070.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2930-5 [8199990.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):653-9; discussion 660 [7676716.001]
  • [Cites] Jpn J Surg. 1991 May;21(3):262-7 [1857030.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2807-12 [1571912.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):839-43 [9128960.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):725-9 [7512130.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:226-30 [10436828.001]
  • [Cites] Cancer Invest. 1993;11(3):241-6 [8485645.001]
  • [Cites] Radiother Oncol. 1992 Jul;24(3):191-4 [1357725.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):1-10 [7678945.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 3:81-6 [8204534.001]
  • [Cites] Int J Pancreatol. 1994 Oct-Dec;16(2-3):121-9 [7868938.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):361-4 [7943597.001]
  • [Cites] Lancet. 1986 Jan 11;1(8472):69-71 [2417075.001]
  • [Cites] Arch Surg. 1993 May;128(5):559-64 [8098206.001]
  • [Cites] Chirurg. 1994 Apr;65(4):246-52 [7912665.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):71-83 [9127177.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):626-30 [7559078.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):102-5 [7819023.001]
  • [Cites] Ann Surg. 1993 May;217(5):447-55; discussion 456-7 [7683868.001]
  • [Cites] Surg Gynecol Obstet. 1981 May;152(5):597-600 [6784258.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1447-52 [3198442.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1012-4 [7648139.001]
  • [Cites] Chirurg. 1992 Jul;63(7):563-7 [1380421.001]
  • [Cites] Baillieres Clin Gastroenterol. 1990 Dec;4(4):969-83 [1706632.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Br J Surg. 1992 Jan;79(1):8-20 [1371087.001]
  • [Cites] Arch Surg. 1978 Apr;113(4):509-11 [76467.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):215-20 [2840866.001]
  • [Cites] Am J Gastroenterol. 1985 Jun;80(6):459-62 [4003374.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Pain. 1990 Jun;41(3):267-71 [1697055.001]
  • [Cites] Am J Surg. 1996 Sep;172(3):297-8 [8862089.001]
  • [Cites] World J Surg. 1981 Sep;5(5):759-61 [6173962.001]
  • [Cites] Am J Surg. 1984 Jun;147(6):793-6 [6203420.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Surg. 1988 Dec;75(12):1166-8 [2466520.001]
  • (PMID = 11276380.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


11. Hayashi N, Hasuike Y, Fukuchi N, Kida H, Tujie M, Yoshida T, Ebisui C, Sakita I, Koshino T, Izumiyama K, Koro T, Fujimoto T: [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1852-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
  • The patient was a 44-year-old man, who was investigated for lateral abdominal pain and liver dysfunction, and subsequently referred to our department with a diagnosis of unresectable intrahepatic cholangiocellular carcinoma (CCC).
  • After 15 courses of home anti-cancer chemotherapy, abdominal CT revealed that the size of intrahepatic metastasis in the left lobe of the liver had not shown growth, whereas other metastitic sites popped up in the caudate lobe, which were free of chemical agent flow.
  • In conclusion, volume reduction surgery followed by transcatheter hepatic arterial chemo infusion might be promising as an effective therapy for non resectable CCC.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Liver Neoplasms / secondary. Lymph Node Excision. Male

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315961.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Lech G, Krasnodebski IW: [Hemobilia of neoplastic origin]. Pol Merkur Lekarski; 2010 Nov;29(173):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Actually the most frequent causes of haemobilia are iatrogenic traumas, due to development of different diagnostic and therapeutic procedures performed endoscopically or laparoscopically.
  • On the other hand cancer disease is the rarest reason of haemobilia.
  • Diagnosing and treatment of cancer disease resulting in haemobilia are still big challenge for up to date medicine.
  • From among all diagnostic procedures angiography of branches of the coeliac trunk seems to be the most important due to it's potentially therapeutic value in case of performing TAE.
  • Actually treatment of haemobilia depends on patient's general condition, tumor localization and size, and intensity of bleeding.
  • Surgery should be performed in cases of haemobilia caused by small, resectable neoplastic tumors.
  • Advanced cancer disease resulting in haemobilia is the indication for TAE and other endoscopic or surgical procedures stopping bleeding and opening the bile duct passage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268920.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement